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Postbariatric hypoglycaemia (PBH) is an increasingly recognized complication of
bariatric surgery, but its effect on daily functioning remains unclear. In this random-
ized, single-blind, crossover trial we assessed driving performance in patients with
PBH. Ten active drivers with PBH (eight females, age 38.2 ± 14.7 years, body mass
index 27.2 ± 4.6 kg/m2) received 75 g glucose to induce PBH in the late postprandial
period and aspartame to leave glycaemia unchanged, on two different occasions. A simu-
lator was driven during 10 minutes before (D0) and 20 (D1), 80 (D2), 125 (D3) and
140 minutes (D4) after the glucose/aspartame ingestion, reflecting the expected blood
glucose (BG) increase (D1), decrease (D2) and hypoglycaemia (D3, D4). Seven driving
features indicating impaired driving were integrated in a Bayesian hierarchical regression
model to assess the difference in driving performance after glucose/aspartame ingestion.
Mean ± standard deviation peak and nadir BG after glucose were 182 ± 24 and 47 ±
14 mg/dL, while BG was stable after aspartame (85 ± 4 mg/dL). Despite the lack of a
difference in symptom perception, driving performance was significantly impaired after
glucose versus aspartame during D4 (posterior probability 98.2%). Our findings suggest
that PBH negatively affects driving performance.
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1 | INTRODUCTION
Postbariatric hypoglycaemia (PBH) is an increasingly recognized late
metabolic complication of bariatric surgery. Prevalence estimates
range widely because of the differing diagnostic criteria used, but may
be as high as 30% of patients undergoing Roux-en-Y gastric bypass
(RYGB).1-3 Affected patients present at least 1 year postoperatively
with frequent hypoglycaemic episodes after meals, particularly after
those with high glycaemic impact.
Despite the high prevalence of PBH cases among the post-
bariatric surgery population, little is known about the impact of PBH
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on the performance of daily activities. Driving is a daily activity that
requires a range of cognitive, psychomotor and other functional abili-
ties. Whilst previous work showed that hypoglycaemia significantly
compromises driving performance in people with diabetes,4 data in
patients with PBH are currently lacking. The aim of this study was to
assess driving performance in patients with PBH.
2 | RESEARCH DESIGN AND METHODS
2.1 | Study design, population and procedures
This prospective, randomized, single-blind, crossover study was con-
ducted at the University Hospital Bern and included active drivers aged
18 years or older with PBH after RYGB. The diagnosis was based on
the documented postprandial hypoglycaemia (interstitial or blood glu-
cose [BG] values <54 mg/dL)5 at times of symptoms, relieved by BG
correction. Exclusion criteria included motion sickness (evaluated using
a test drive in the simulator), weight changes of 5% or more
within 3 months, historical or current diabetes, haemoglobin less than
11 g/dL, pregnancy or breastfeeding, severe organ dysfunction and
medications known to interfere with BG. The study was conducted in
accordance with Good Clinical Practice and the Declaration of Helsinki
after local Ethics Committee approval (2020–00400). All participants
provided written informed consent prior to study-related procedures.
The study was registered on ClinicalTrials.gov (NCT04330196).
After screening, which also included a 20-minute test drive in the
driving simulator to familiarize participants with the procedures of the
main experiments, participants attended two visits in random order
separated by 48 hours or longer. During the 48 hours before each visit,
they adhered to a standardized, weight-maintaining diet (identical for
both conditions) and refrained from alcohol, caffeine and physical activ-
ity. Participants were also fitted with a continuous glucose monitor and
were instructed to correct BG values of less than 54 mg/dL. After an
overnight fast, they were admitted to the clinical research unit and
ingested 75 g of glucose (GLU) or 700 mg of aspartame (ASP) dissolved
in 200 mL of water within 5 minutes in an upright sitting position.
Participants were blinded to the type of drink and their BG values dur-
ing the whole experiment. GLU was administered to trigger PBH in the
late postprandial period, whereas ASP was used as a control condition,
because it has no impact on glycaemia.6 The dose of ASP was selected
to match the sweetness of the 75 g of GLU according to a prestudy
dose-finding experiment in five healthy volunteers considering the
range of reported sweetness equivalences in the literature.6,7 An intra-
venous catheter was inserted in a cubital vein for frequent BG sampling
using a Biosen C-Line glucose analyser (EKF Diagnostics, Barleben,
Germany) and GLU administration in cases of severe hypoglycaemia or
BG less than 27 mg/dL irrespective of symptoms.
During the visits, participants performed 10-minute drives in a
simulator (Carnetsoft BV, Groningen, The Netherlands) before
(D0) and at 20 (D1), 80 (D2), 125 (D3) and 140 minutes (D4) after
GLU/ASP intake. The time points were selected based on the
expected glycaemic trajectory in PBH3: BG increase (D1), decrease
(D2) and hypoglycaemia (D3 and D4). The simulator scenarios during
the different driving phases resembled the same rural environment,
but each had a shifted starting point. The order of scenarios was ran-
domly generated and kept identical for both conditions.
We assessed cognitive function using the Digit Symbol Substitu-
tion Test (DSST)8 135 minutes after GLU/ASP, and symptom percep-
tion using the Edinburgh Hypoglycemia Symptom Scale9 10, 40,
100, 135 and 150 minutes after GLU/ASP (Figure S1).
2.2 | Endpoints and study analysis
The primary endpoint was the difference in driving performance
between GLU and ASP across seven driving features that were com-
puted over the glycaemic trajectory: speed and safety margin violation
(reflecting traffic rule violations), longitudinal and lateral acceleration,
steering wheel, braking pedal and gas pedal acceleration (indicating
unsteady and nervous behaviour). The difference in z-score between
GLU and ASP for each patient (p), driving phase (d) and feature (f ) was
calculated with a Bayesian hierarchical regression model as follows:
GLUDrivingf,d,p ASPDrivingf,d,p ¼αpþOþDþDf ,
where αp accounts for subject-specific variation, O for the visit order,
D for the pooled fixed-effect across all features, and Df for the
feature-specific random effect (for further details, see Appendix S1).
An analogous Bayesian approach (accounting for subject-specific vari-
ation and visit order) was used to analyse cognitive performance and
symptom perception. Further endpoints were mean, peak and nadir
BG as well as cognitive performance and symptom perception.
Because of the lack of pre-existing literature on the primary end-
point, a formal sample size calculation was not applicable. The study
was of an exploratory nature, aiming to recruit up to 13 participants,
with at least 10 participants completing the study (dropout rate 20%).
TABLE 1 Baseline characteristics
Number of subjects = 10
Age (y) 38.2 ± 14.7
Sex (f, m)a 8 f, 2 m
Body weight (kg) 76.4 ± 10.3
Current BMIb (kg/m2) 27.2 ± 4.6
BMI presurgery (kg/m2) 42.0 ± 2.4
Total weight loss (%) 35.0 ± 10.9
Years since Roux-en-Y gastric
bypass surgery
5.1 ± 2.5
HbA1c (%, mmol/mol) 5.2 ± 0.3, 33 ± 4
Driving experience (y) 17.4 ± 14.8
Km driven per year 13 150 ± 8538
Note: Data are presented as mean ± standard deviation.
af, female; m, male.
bBMI, body mass index.
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All statistical analyses were performed with the statistical soft-
ware R (version 4.0.2). Endpoints are presented as the posterior mean
(95% credible interval [CI]) and posterior probability of the z-score dif-
ference or mean ± standard deviation. Statistical significance was con-
sidered as CI excluding 0.
3 | RESULTS
From July to December 2020, 17 individuals were invited for screen-
ing, of whom 12 were randomized (five individuals were excluded as a
result of motion sickness) and 10 had complete data and were
included in the final analysis (Figure S2). Participants (8/10 females)
were aged 38.2 ± 14.7 years, operated on 5.1 ± 2.5 years earlier, and
showed a total weight loss of 35.0% ± 10.9%. Additional baseline
characteristics are shown in Table 1.
Peak and nadir BG after GLU were 182 ± 24 and 47 ± 14 mg/dL
at 32 ± 13 and 121 ± 14 minutes (Figure 1A). Nadir BG was more
than 54 mg/dL in two participants (60 and 75 mg/dL, respectively),
whilst one participant required intravenous GLU because of BG of
25 mg/dL. After GLU, BG before D1, D2, D3 and D4 was 142 ± 25,
91 ± 27, 54 ± 11 and 60 ± 12 mg/dL, respectively (Figure S3). BG
remained stable after ASP (85 ± 4 mg/dL; Figure S4).
Baseline BG (88 ± 6 vs. 87 ± 5 mg/dL) and driving performance
during D0 (0.08 [0.58, 0.49]) were comparable between GLU and
ASP. Whilst no statistically significant differences between the condi-
tions were found during D1, D2 and D3, GLU significantly reduced
driving performance during D4 (0.42 [0.03, 0.80]; Figure 1B) com-
pared with ASP. Accordingly, the posterior probability for impaired
driving after GLU versus ASP was 15.5% for D1, 84.7% for D2, 84.8%
for D3 and 98.2% for D4. Differences in each driving feature for
D1–D4 between GLU and ASP are shown in Figure S5.
The DSST performance was significantly lower after GLU versus
ASP (12.5 pairs [23.90, 1.73]), corresponding to a posterior prob-
ability of 99%. Symptom perception was similar between GLU and
ASP throughout the experiment and participants reported only a few
autonomic and neuroglycopaenic symptoms (Figure 1C and Table S1).
No adverse events occurred.
4 | DISCUSSION
This study explored the impact of blinded postprandial hypoglycaemia
versus euglycaemia induced by ingesting GLU versus ASP on driving
performance in patients with confirmed PBH. Impaired driving perfor-
mance was observed in the late postprandial period, 140 minutes
after GLU and was preceded by a lower cognitive test score at
135 minutes. Conversely, symptom perception did not differ between
GLU and ASP.
Unlike in people with diabetes in whom the negative effects of
hypoglycaemia on several aspects of daily life,10 including driving
performance,4 are well established, less is known about the implica-
tions of PBH. In fact, the high prevalence of asymptomatic PBH11 has
caused uncertainty and scepticism regarding the relevance of this con-
dition. Compared with hypoglycaemia in diabetes, PBH is character-
ized by a distinct postprandial BG pattern, with a fast BG increase to
peak values within 30 minutes and rapid decrease to hypoglycaemia
90–140 minutes postprandially.3 Although recent work suggests that
BG dynamics may be of particular relevance in PBH,12 driving perfor-
mance did not differ between GLU and ASP in phases of increasing
and decreasing BG. Conversely, impaired driving performance, as
F IGURE 1 (A) Mean blood glucose (mg/dL) over time after
glucose (GLU) and aspartame (ASP). The whiskers display the standard
deviation. (B) Estimated difference in driving features between GLU
and ASP for each driving phase (shaded in grey). Positive difference in
z-score indicates deteriorated driving performance in GLU compared
with ASP. The black and grey bars display the 80% and 95% credible
intervals. (C) Mean perceived total, autonomic, neuroglycopaenic and
malaise symptoms during GLU and ASP visits assessed with the
Edinburgh Hypoglycemia Symptom Scale (EHSS). The range for the
total EHSS score is 11–77. The range for the autonomic,
neuroglycopaenic and malaise EHSS score is 4–28, 5–35 and 2–14,
respectively. D1 – D4, driving phases 1–4
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reflected by traffic rule violations and unsteady and nervous driving,
was observed with low BG levels, especially if prolonged. This was
further supported by a lower cognitive score suggesting that
neuromotor skills deteriorate with prolonged hypoglycaemia, even if
BG recovered from nadir. Similarly, impaired neuromotor function in
adults with type 1 diabetes in a hypoglycaemic clamp study persisted
for up to 10 minutes after restoration of euglycaemia.13
Worryingly, we found no significant difference in reported hyp-
oglycaemic symptoms after GLU compared with ASP, which is in line
with previous studies supporting a high prevalence of asymptomatic
PBH patients.11 The paucity of symptoms may indicate worrying
hypoglycaemia unawareness as a result of repeated hypoglycaemia.14
This may impede corrective self-treatment of hypoglycaemia, which
corroborates the need for detection and warning approaches in this
population.
The strengths of this study are the novelty of the research ques-
tion addressing the impact of PBH on driving performance, the stan-
dardized design and the inclusion of PBH cases who were blinded to
both the provocative stimulus and their glycaemia. We acknowledge
the small sample size and the unclear transferability of findings from a
simulator to driving risks in real-life conditions. Further studies
employing larger sample sizes as well as non-affected surgical and
non-surgical controls are warranted to assess the consequences
(e.g. accidents) of impaired driving during PBH, and to also contrast
the impact of PBH on driving with the effect of other compromised
health states (e.g. intoxication, sleep deprivation). Although the driving
scenarios exclusively reflected rural environments, this choice was
based on their balanced combination of various discriminative driving
elements, such as intersections, traffic lights and curves, as well as
straight lines. Of note, the nadir BG of two participants during the test
was more than 54 mg/dL, despite documented prestudy values of less
than 54 mg/dL. This inconsistency could be attributable to a psycho-
logical stress-related increase in glycaemia, in line with previous
reports.15 Glycaemia was not standardized using clamp procedures,
however, our design allowed replicating the natural course of PBH
including gut stimulation, which is critically involved in its underlying
pathophysiology.16
In conclusion, we report impaired driving performance during
PBH alongside a paucity of symptoms. This calls for novel approaches
for early PBH detection and prediction, enabling timely preventive or
corrective actions.
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